DiaSorin and BARDA Team Up for Point-of-Care Test Equipment
Italy-based DiaSorin and the Biomedical Advanced Research and Development Authority (BARDA) are teaming up to gain 510(k) clearance of the company’s Liaison NES point-of-care test instrument for performing tests for viral and bacterial pathogens.
The Liaison NES is designed to allow untrained operators to perform testing for viral and bacterial pathogens to support the decentralization of diagnostic testing beyond the hospital setting. The initial focus will be on a combination test for SARS-CoV-2 and influenza A/B.
BARDA was created to address gaps in the U.S. government’s medical countermeasure development and procurement process.
Future product development will focus on additional respiratory infections and sexually transmitted diseases, among others, the company said.
The financial terms of the collaboration were not disclosed.